SCHEMBL977301

SCHEMBL977301

O[C@H](c1c2ccccc2cc2ccccc12)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP1A2 P05177 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
GLA P06280 1/20 0.39
CYP2C19 P33261 1/20 0.39
TRPM4 Q8TD43 1/20 0.38
PTPN1 P18031 1/20 0.38
HIF1A Q16665 1/20 0.37
CYP1B1 Q16678 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
HTR2A P28223 1/20 0.36
NQO2 P16083 1/20 0.36
DHODH Q02127 1/20 0.36
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075110 1.00 ALDH1A1 (0.39) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL2482183 1.00 ALDH1A1 (0.39) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL8745296 0.87 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL14155951 0.85 MEN1 (0.37) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL7074543 0.79 PTPN22 (0.47) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL29946603 0.79 PTPN22 (0.47) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL27925964 0.79 L3MBTL1 (0.37) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL14294943 0.78 DHODH (0.32) PTPN1DHODH
SCHEMBL10132729 0.78 DHODH (0.32) PTPN1DHODH
SCHEMBL488964 0.76 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4637708-A2 SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE Novaliq GmbH (DE) 2025-10-29 EP claimed
CN-119894883-A Methods and processes for preparing MCT4 inhibitors 维托尔股份有限公司 2025-04-25 CN claimed
WO-2024133913-A9 SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE NOVALIQ GMBH (DE) 2025-03-20 WO claimed
CN-116554117-B Preparation method of hapten for detecting oxadixyl in tobacco and application of hapten obtained by preparation method 云南省烟草质量监督检测站 2025-02-07 CN claimed
CN-118496133-A Method for synthesizing thioamide compound by using aryl chloride and isonitrile 华南理工大学 2024-08-16 CN claimed
WO-2024133913-A2 SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE NOVALIQ GMBH (DE) 2024-06-27 WO claimed
CN-117209374-A Hydroxyl valeric acid compound containing quaternary carbon center and synthesis method thereof 四川大学 2023-12-12 CN claimed
CN-114773175-B Preparation method of chiral tertiary alcohol benzo-fused bicyclo [ m.3.0] alkanone compound 上海毕得医药科技股份有限公司 2023-11-03 CN claimed
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US claimed
EP-3732175-B1 A CATALYST COMPOSITION FOR A PRODUCING PROCESS OF AN UNSATURATED CARBOXYLIC ACID SALT AND ITS DERIVATIVES FROM CARBON DIOXIDE AND OLEFIN PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) 2023-08-16 EP claimed
CN-116554117-A Preparation method of hapten for detecting oxadixyl in tobacco and application of hapten obtained by preparation method 云南省烟草质量监督检测站 2023-08-08 CN claimed
WO-2023109576-A1 COPPER CONDUCTIVE INK, FLEXIBLE SUBSTRATE, AND PREPARATION METHOD FOR FLEXIBLE SUBSTRATE 深圳先进技术研究院 2023-06-22 WO claimed
CN-114773175-A Preparation method of chiral tertiary alcohol benzo-fused bicyclo [ m.3.0] alkanone compound 上海毕得医药科技股份有限公司 2022-07-22 CN claimed
WO-2025201236-A1 MCT4 INHIBITORS AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京福元医药股份有限公司 2025-10-02 WO disclosed
US-12384757-B2 Methods of synthesizing substituted pyridinone-pyridinyl compounds ACLARIS THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
CN-120202199-A MC4R antagonist compound, pharmaceutical composition and application thereof in medicine 长春金赛药业有限责任公司 2025-06-24 CN disclosed
US-4968678-A NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY (US) 1990-11-06 US disclosed
EP-0386920-A2 2-Hydroxy-3-thienyloxypropylamino derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-09-12 EP disclosed
EP-0368410-A2 Optically active benzoxazines and bezothiazines and a process for their stereospecific preparation GIST-BROCADES N.V. (NL) 1990-05-16 EP disclosed
EP-0302826-A2 Process for the preparation of unsaturated amino acid compounds CIBA-GEIGY AG (CH) 1989-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384757-B2 Methods of synthesizing substituted pyridinone-pyridinyl compounds PIR, PUM1, ZRANB2 ALDH1A1 873/4885MEN1 779/4885KMT2A 2235/4885
US-11760750-B1 Process for preparing levoketoconazole KHK, KYAT3, PLK3 ALDH1A1 2659/4885MEN1 2073/4885KMT2A 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.